Brainstorm Cell Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Brainstorm Cell Therapeutics's estimated annual revenue is currently $7.5M per year.
- Brainstorm Cell Therapeutics's estimated revenue per employee is $192,308
- Brainstorm Cell Therapeutics's total funding is $51.6M.
- Brainstorm Cell Therapeutics has 39 Employees.
- Brainstorm Cell Therapeutics grew their employee count by 11% last year.
Brainstorm Cell Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Brainstorm Cell Therapeutics?
BrainStorm (OTC.BB: BCLI) is an emerging company developing stem cell therapeutic products based on breakthrough technologies. BrainStorm\'s core technology, NurOwn™, was developed through a collaboration between prominent neurologist, Prof. Eldad Melamed, Head of Neurology of the Rabin Medical Center and member of the Scientific Committee of Michael J. Fox Foundation for Parkinson\'s Research and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University.keywords:N/A
Number of Employees
Employee Growth %
Brainstorm Cell Therapeutics News
MiNK Therapeutics (NASDAQ:INKT) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Survey. Posted by admin on Apr 24th, 2022.
As a group, equities research analysts predict that Brainstorm Cell Therapeutics will post -0.87 earnings per share for the current fiscal year.
Brainstorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended September 30, 2021, and provided a corporate update. "We made strong progre ...
Company Overview BrainStorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis ("ALS", also known as ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|